MedTrace Logo

A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

NCT07126171 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-08-17

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Reduning Injection in the treatment of chikungunya fever

Conditions

  • Chikungunya Fever

Interventions

DRUG

Reduning injection

reduning Injection, intravenous drip, 20 ml per time, once a day;

DRUG

The simulant of Reduning Injection

The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day

Sponsors & Collaborators

  • Jiangsu Kanion Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-28
Primary Completion
2025-11-26
Completion
2026-02-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07126171 on ClinicalTrials.gov